Elderly rats fed with a high-fat high-sucrose diet developed sex-dependent metabolic syndrome regardless of long-term metformin and liraglutide treatment.
Front Endocrinol (Lausanne) · 2023
Last updated 2026-05-28In a study of elderly rats fed a high-fat, high-sucrose diet, long-term treatment with metformin or liraglutide did not prevent prediabetes or diabetes. The drugs had different effects by sex: liraglutide improved liver and muscle health in males but increased insulin resistance in females.
AI summary of the abstract below.
| Journal | Front Endocrinol (Lausanne), 2023 |
|---|---|
| Citations | 3 |
| Relative citation ratio | 0.46 |
| NIH percentile | 27 |
| Molecules | liraglutide |
| Conditions studied | Type 2 Diabetes, Obesity, Cardiovascular Risk Reduction, Mash |
Abstract
AIM/INTRODUCTION: The study aimed to determine the effectiveness of early antidiabetic therapy in reversing metabolic changes caused by high-fat and high-sucrose diet (HFHSD) in both sexes.
METHODS: Elderly Sprague-Dawley rats, 45 weeks old, were randomized into four groups: a control group fed on the standard diet (STD), one group fed the HFHSD, and two groups fed the HFHSD along with long-term treatment of either metformin (HFHSD+M) or liraglutide (HFHSD+L). Antidiabetic treatment started 5 weeks after the introduction of the diet and lasted 13 weeks until the animals were 64 weeks old.
RESULTS: Unexpectedly, HFHSD-fed animals did not gain weight but underwent significant metabolic changes. Both antidiabetic treatments produced sex-specific effects, but neither prevented the onset of prediabetes nor diabetes.
CONCLUSION: Liraglutide vested benefits to liver and skeletal muscle tissue in males but induced signs of insulin resistance in females.
Verbatim abstract via PubMed 37929025 ↗
Related research
- Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes.
- A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management.
- Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study.
- Liraglutide and Renal Outcomes in Type 2 Diabetes.
- Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial.
- The arcuate nucleus mediates GLP-1 receptor agonist liraglutide-dependent weight loss.
- Effect of Weekly Subcutaneous Semaglutide vs Daily Liraglutide on Body Weight in Adults With Overweight or Obesity Without Diabetes: The STEP 8 Randomized Clinical Trial.
- The Discovery and Development of Liraglutide and Semaglutide.